ライフサイエンスコーパス: IgA2

1 ry capacity of IgA1, making it comparable to IgA2.

2 to IgG3/IgG1/IgA1/IgG2/IgG4 and later to IgE/IgA2.

3 , with IgA1 possessing more sialic acid than IgA2.

4 glycans are almost exclusively recognized by IgA2.

5 ere similar between wild-type and engineered IgA2.

6 of neutrophil granulocytes by both IgA1 and IgA2.

7 ly positive for anti-chlamydia IgG2, IgG4 or IgA2.

8 its native ligand as well as human IgA1 and IgA2.

9 uch a T-shape may be common to both IgA1 and IgA2.

10 Bacteroidetes is preferentially targeted by IgA2.

11 rum levels of IgA1 are greater than those of IgA2.

12 re are two subclasses of human IgA, IgA1 and IgA2.

13 (3 of 5), IgG2 (2 of 5), IgA1 (4 of 5), and IgA2 (1 of 5).

14 study, we report a novel, to our knowledge, IgA2 Ab against the epidermal growth factor receptor gen

15 We used recombinant human IgA1 and human IgA2 Abs and domain swapped IgA/IgG chimeras to determin

16 The 2F5 IgG1 and IgA2 acted synergistically to fully block HIV-1 transfer

17 Whereas IgA2 acts pro-inflammatory on neutrophils and macrophage

18 The major pathway for the clearance of all IgA2 allotypes is the liver.

19 G3 appears common, but IgG1, IgG2, IgA1, and IgA2 also arise, indicating a continuing influence of a

20 roup of urine samples, the prevalence of the IgA2 AMA was 6/18 (33%), significantly lower than in mat

21 lizing anti-HIV-1 2F5 IgG1, and compared 2F5 IgA2 and IgG binding affinity and functional activities.

22 tibodies of protease-insensitive subclasses (IgA2 and IgG) nor those directed against heterologous ca

23 IgG2, IgA2 and IgM were inert.

24 aride-specific immunoglobulin A (IgA), IgA1, IgA2 and secretory component, IgG antibodies, and total

25 y IgA1 and IgA2 in the small intestine, IgA1+IgA2+ and IgA1-IgA2+ bacteria coexist in the colon lumen

26 enerated chimeric V gene-matched human IgA1, IgA2, and control IgG1 autoantibodies directed against t

27 It exists as two subclasses IgA1 and IgA2, and IgA2 is found in at least two allotypic forms,

28 ones, derived from IgG1, IgG2/3, IgG4, IgA1, IgA2, and the joining chain from dimeric IgA.

29 e majority of stools contained both IgA1 and IgA2, and the relative proportions did not change follow

30 in the small intestine, IgA1+IgA2+ and IgA1-IgA2+ bacteria coexist in the colon lumen, where Bactero

31 constructed from a hybrid comprised of human IgA2 bearing half of the human IgA1 hinge region.

32 We found that 2F5 IgA2 bound to the gp41 membrane proximal external region

33 The rapid clearance of IgA2 but not IgA1 through the liver may in part explain

34 her, our findings indicate that HDM-specific IgA2, but not IgA1, levels in serum and saliva are reduc

35 er and how the human IgA subclasses IgA1 and IgA2 contribute to the clinical status of house dust mit

36 Overall, our studies indicate that for IgA2 covalent assembly of the H and L chains requires th

37 onstrate that recombinant, chimeric IgA1 and IgA2 differ in their pharmacokinetic properties.

38 e show that the two IgA subclasses (IgA1 and IgA2) differ in their effect on immune cells due to dist

39 Thus, gut IgA1 and IgA2 emerge from clonally related PCs and show unique ch

40 In contrast, the IgA2 epitope included a unique conformational motif on t

41 Increased IgG4-EW, IgA-EW, and IgA2-EW during eOIT are associated with clinical respons

42 Relative increases in IgG4-EW, IgA-EW, and IgA2-EW were observed in responders (P = 0.024, 0.024, a

43 e two subclasses of IgA, IgA1 and IgA2, with IgA2 existing as three allotypes, IgA2m(1), IgA2m(2) and

44 IgA2 exists as two known allotypes, IgA2 m(1) and IgA2 m

45 e the role of the CH1 domain, we constructed IgA2 from the broadly neutralizing anti-HIV-1 2F5 IgG1,

46 ecular modeling, we probed distinct IgA1 and IgA2 glycoforms for binding to four different FcalphaRI

47 Compared to IgA1, IgA2 has a much shorter hinge region, which joins the tw

48 Moreover, IgA1 and IgA2 have different glycosylation profiles, with IgA1 po

49 Although both types of human IgA (IgA1 and IgA2) have several N-glycans as post-translational modif

50 using molecular dynamics to generate random IgA2 hinge structures, to which homology models for the

51 and IgA2 m(2) with a recently reported novel IgA2 (IgA2(n)) possibly representing a third allotype.

52 IgG4/IgE, IgA/IgE, and IgA2/IgE ratios for EW and IgA/IgE ratio for OVA were fo

53 ed that IgG2 in desensitization, IgG1, IgA1, IgA2, IgG4, and IgD in remission, and IgD in NT were pre

54 lex O- and N-glycosylation of serum IgA1 and IgA2 in IgAN, we used liquid chromatography-mass spectro

55 llergic controls, but HDM-specific levels of IgA2 in saliva were decreased in allergic subjects.

56 We observed a relative loss of IgA2 in symptomatic disease despite an overall expansion

57 t commensals are dually targeted by IgA1 and IgA2 in the small intestine, IgA1+IgA2+ and IgA1-IgA2+ b

58 exists as two subclasses IgA1 and IgA2, and IgA2 is found in at least two allotypic forms, IgA2m(1)

59 Our previous studies indicated that in IgA2 lacking Cys(133), a disulfide bond forms between th

60 ected, and HDM-specific, IgE, IgG4, IgA1 and IgA2 levels were determined.

61 and eczema showed a significant decrease in IgA2-levels compared to patients who suffered from rhini

62 IgA2 exists as two known allotypes, IgA2 m(1) and IgA2 m(2) with a recently reported novel I

63 Only a small fraction of IgA2 m(1) assembles through disulfide-bonded HL.

64 ow some HL, H2L2, and H4L4J, suggesting that IgA2 m(1) can exist either as a form lacking H-L disulfi

65 IgA2 m(1) differs from IgA2 m(2) and the IgA2(n) at two

66 However, IgA2 m(2) and the IgA2(n) but not IgA2 m(1) form an H-L disulfide in the absence of Cys133

67 of the H chain with the L chains while human IgA2 m(1) has been reported to lack a covalent bond betw

68 (2) and the IgA2(n) at two positions in CH1; IgA2 m(1) has Pro212 and Pro221 whereas IgA2 m(2) and th

69 rotein purified from culture supernatants of IgA2 m(1) show some HL, H2L2, and H4L4J, suggesting that

70 nstrate that it is the presence of Pro221 in IgA2 m(1) that interferes with the H-L disulfide in the

71 In contrast, the major intermediate for IgA2 m(1) with Pro(221) assembly was H(2) even though bo

72 IgA2 m(1) differs from IgA2 m(2) and the IgA2(n) at two positions in CH1; IgA2

73 However, IgA2 m(2) and the IgA2(n) but not IgA2 m(1) form an H-L

74 CH1; IgA2 m(1) has Pro212 and Pro221 whereas IgA2 m(2) and the IgA2(n) have Ser212 and Arg221.

75 exists as two known allotypes, IgA2 m(1) and IgA2 m(2) with a recently reported novel IgA2 (IgA2(n))

76 lfide-bonding pattern; in IgA1, IgA2(n), and IgA2 m(2), a disulfide bond connects a cysteine residue

77 th previous scattering modelling of IgA1 and IgA2(m)1 suggests that the hinge of IgA1 and IgD are mor

78 solved analysis of IgE, IgG4, IgA, IgA1, and IgA2 may identify potential biomarkers of SU in OIT subj

79 o polarized macrophages mediated significant IgA2-mediated ADCC.

80 ith decreased IgMD(+), IgG2(+), IgA1(+), and IgA2(+) memory B cells (P <= .032) and elevated IgM (P =

81 The IgA2 models show full steric access to the two FcalphaRI

82 Functionally, compared with IgG1, 2F5 IgA2 more efficiently blocked HIV-1 transcytosis across

83 and two IgA1 myeloma proteins but not to two IgA2 myeloma proteins.

84 IgA2 m(1) differs from IgA2 m(2) and the IgA2(n) at two positions in CH1; IgA2 m(1) has Pro212 an

85 However, IgA2 m(2) and the IgA2(n) but not IgA2 m(1) form an H-L disulfide in the a

86 Pro212 and Pro221 whereas IgA2 m(2) and the IgA2(n) have Ser212 and Arg221.

87 t covalent assembly of the H and L chains in IgA2(n) requires hinge-proximal Cys(241) and Cys(242) in

88 riments, we have demonstrated that wild-type IgA2(n) with Arg(221) and Cys(241) and Cys(242) assemble

89 A2 m(2) with a recently reported novel IgA2 (IgA2(n)) possibly representing a third allotype.

90 L chain disulfide-bonding pattern; in IgA1, IgA2(n), and IgA2 m(2), a disulfide bond connects a cyst

91 g as three allotypes, IgA2m(1), IgA2m(2) and IgA2(n).

92 the female genital tract secretions in which IgA2 occurs in slight excess, the distribution of IgA su

93 impact of N-glycan modifications of IgA1 and IgA2 on binding to the Fcalpha receptor (FcalphaRI), whi

94 We show here that intestinal IgA1+ and IgA2+ PCs co-emerged early in life, comparably accumulat

95 IgA2+ PCs were extensively clonally related to IgA1+ PCs

96 gA1+ plasmablasts, a depletion in long-lived IgA2+ PCs, and increased SIgA1+SIgA2+ gut microbiota.

97 n blood as two isotypes, IgA1 and IgA2, with IgA2 present as three allotypes: IgA2m(1), IgA2m(2), and

98 Ricin bound to both human IgA1 and IgA2, primarily via N-linked oligosaccharide side chains

99 tive bacteria, but ZmpB had neither IgA1 nor IgA2 protease activity.

100 Furthermore, IgA2 proteins that lack the hinge region with O-linked g

101 ubclass profiles were IgG1 > IgG3 and IgA1 > IgA2, respectively.

102 However, only V-FP(imm) induced cervical IgA2-restricted Ab to the bacterial LPS vaccine componen

103 display a shift toward the pro-inflammatory IgA2 subclass, which is associated with higher disease a

104 itis (AR) and controls, and assayed for IgA1/IgA2 synthesis, pIgR expression, production of secretory

105 IgA1 and IgA2 that are not rapidly eliminated by the ASGR are bot

106 human lactoferrin, secretory component, and IgA2 that were shown to be present on the surface of the

107 expansion, and isotype skewing from IgA1 and IgA2 to IgG1.

108 (PCs) expressing immunoglobulin A1 (IgA1) or IgA2, two structurally distinct IgA subclasses with elus

109 ural features of N-glycosylation of IgA1 and IgA2 were associated with IgAN and glomerular function i

110 n convalescent plasma, while IgG2, IgG4, and IgA2 were not informative.

111 coid (OVM)-specific levels of IgA, IgA1, and IgA2 were quantified by ELISA.

112 type exists in mice, humans secrete IgA1 and IgA2, whose respective relations with the microbiota rem

113 s, there are two subclasses of IgA, IgA1 and IgA2, with IgA2 existing as three allotypes, IgA2m(1), I

114 )A exists in blood as two isotypes, IgA1 and IgA2, with IgA2 present as three allotypes: IgA2m(1), Ig